ENSURING THE STERILITY OF SUBSTITUTION THERAPY MEDICATIONS FOR DRY-EYE SYNDROME TREATMENT AFTER OPENING THE ORIGINAL PACKAGING

Yuliia Tomashevska; Olena Kryvoviaz

doi:10.23856/4433

Yuliia Tomashevska National Pirogov Memorial Medical University https://orcid.org/0000-0001-9708-1887
Olena Kryvoviaz National Pirogov Memorial Medical University https://orcid.org/0000-0001-5441-1903

Keywords: eye medications, anti-microbial stability, preservatives, containers

Abstract

The aim of the article is to study the assortment of the additive agents in the composition of dry-eye syndrome substitution therapy medications registered in Ukraine, which may increase the anti-microbial stability of the solution as well as types of packaging of preservative free substitution therapy medications.

The methodology of the research includes the content-analysis of the information on the substitution therapy medications composition, provided in the insert of the medication as well as the study of the type of original packaging and the way it influences the preservation of sterility and properties of the substitution therapy medications.

Provision of clear information in the labeling and the insert of the medication regarding the presence, name and quantity of a preservative (with the use of the term “preservative”) is a necessary and often one of the determining factors in treatment selection for patients with dry-eye syndrome. This is determined by the fact that certain agents (or their combination) may perform different functions in a medical form acting, depending on the, for instance, concentration, as preservatives, components of buffer solutions, antioxidants or isotonic substances.

The results of the study show that as of December, 2020 only a few of substitution therapy medications presented on the pharmaceutical market of Ukraine contain such information.

References

1. Bron, A. J., dePaiva, C. S., Chauhan, S. K. et al. (2017). TFOS DEWS II pathophysiology report. The Ocular Surface, vol. 15, no. 3, pp. 438-510.
2. Craig, J. P., Nichols, K. K., Akpek, E. K. et al. (2017). TFOS DEWS II definition and classification report. The Ocular Surface, vol. 15, no. 3, pp. 276-283.
3. Derzhavna farmakopeia Ukrainy 2-e vyd. [State Pharmacopoeia of Ukraine 2-nd ed.] (2015). Kharkiv: Derzhavne pidpryiemstvo "Ukrainskyi naukovyi farmakopeinyi tsentr yakosti LZ". [in Ukrainian]
4. Derzhavnyj reyestr likars’kykh zasobiv Ukrayiny [State Register of Medicines of Ukraine] (2019). Retrieved from: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument. [in Ukrainian]
5. Derzhavnyj reyestr medychnoyi tekhniky ta vyrobiv medychnoho pryznachennya [State Register of Medical Equipment and Medical Devices] (2019). Retrieved from: http://dls.gov.ua/wp-content/uploads/2018/07/%D0%A0%D0%B5%D0%B5%D0%B5%D1%81%D1%82%D1%80.pdf. [in Ukrainian]
6. Dovidnyk likars’kykh zasobiv Kompendium [Medicines Reference Compendium]. (2019). Retrieved from: https://compendium.com.ua/uk. [in Ukrainian]
7. Elmer, Y. Tu. (2014). Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives. Saudi Journal of Ophthalmology, vol. 28, no. 3, pp. 182-187.
8. Epstein, S. P. et al. (2009). Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. Journal of Ocular Pharmacology and Therapeutics, vol. 25, no. 2, pp. 113-119.
9. Jones, L., Downie, L. E., Korb, D. et al. (2017). TFOS DEWS II management and therapy report. The Ocular Surface, vol. 15, no. 3, pp. 575-628.
10. Kryvoviaz, O. V., Tomashevska, Yu. O. (2019). Zasoby dlya zamisnoyi terapiyi syndromu sukhohooka: analiz farmacevtychnoho rynku Ukrayiny [Remedies for substitution therapy of the dry eye syndrome: analysis of the pharmaceutical market of Ukraine]. Pharmaceutical Review, no. 4, pp. 37-44. [in Ukrainian]
11. Makarenko, O. V., Kryvoviaz, O. V., Tomashevska, Yu. O. (2015). Vplyv dopomizhnykh rechovyn u protyhlaukomnykh ochnykh krapliakh na pokaznyk yakosti zhyttia za kryteriiem chastoty pobichnykh efektiv [Influence of excipients in antiglaucoma eye drops on the quality of life by the criterion of frequency of side effects]. Farmatsevtychnyi Zhurnal, no. 3, pp. 39-44. [in Ukrainian]
12. Marx, D., Birkhoff, M. (2010). New devices for dispensing ophthalmic treatments may be the key to managing the life cycles of established products. Drug Development & Delivery, vol. 10, no. 9, pp. 16-21.
13. Marx, D., Birkhoff, M. (2015). Original packaging – Ophthalmic Squeeze Dispenser (OSD): Does One Size Fit All? Drug Development & Delivery, vol. 15, no. 8, pp. 41-49.
14. McMonnies, C. W. (2021). Why the symptoms and objective signs of dry eye disease may not correlate. Journal Of Optometry, vol. 14, no. 1, pp. 3-10.
15. Syndrom sukhoho oka. Klinichna nastanova, zasnovana na dokazakh [Dry eye syndrome. Evidence-based clinical guidance]. (2019). Retrieved from: http://mtd.dec.gov.ua/index.php/uk/haluzevi-standarty-ta-klinichni-nastanovy/item/421-syndrom-sukhoho-oka. [in Ukrainian]